Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MmO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1T3SmlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP NXvENFl7W0GQR1XS
CAL-51 cell Mo\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlTkTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?= MVjTRW5ITVJ?
ABC-1 cell NHLrVo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlUhdk1? M{\MbXNCVkeHUh?=
A2780 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWnnXlZqUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTl2IH7N NGeyW3VUSU6JRWK=
ES1 cell NXrGeXdWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1nVPGlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? M2LOXHNCVkeHUh?=
HUTU-80 cell M1PDN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYjwdWI1UW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OUGgcm0> Mn3tV2FPT0WU
NCI-H292 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2= NXy2XHJ1W0GQR1XS
NB69 cell M37KUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rhbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlIhdk1? NGC2V|BUSU6JRWK=
ES8 cell NUPsRpFsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2XTOmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNkBvVQ>? M{C0fnNCVkeHUh?=
BCPAP cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVG4PGRLUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= NF;td3dUSU6JRWK=
T-24 cell Mk\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7reJZKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2KG6P M4Pj[nNCVkeHUh?=
EW-16 cell M1;XUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn64TY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlEhdk1? NXm3coc2W0GQR1XS
OVCAR-5 cell NV;P[lBwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYOyeJdzUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=> M{DuPXNCVkeHUh?=
SF126 cell MmPSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvUO|ZXUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTVibl2= MnHVV2FPT0WU
KP-4 cell NFXw[o9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfVTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6xO{BvVQ>? MYLTRW5ITVJ?
GAMG cell MmfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnfsTY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NUBvVQ>? M{\wenNCVkeHUh?=
HOS cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHTd4lKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVMhdk1? NVTT[4RyW0GQR1XS
CHL-1 cell Ml\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2TrdGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlgyKG6P NV7kfVJ6W0GQR1XS
AGS cell MnmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYfCW2FbUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P MWDTRW5ITVJ?
MDA-MB-157 cell MlLzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N M4DsOHNCVkeHUh?=
HSC-3 cell NVTZWmdbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnLZTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? NFPIS3VUSU6JRWK=
CAL-72 cell NIPnO|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjwTY5pcWKrdHnvckBw\iCqdX3hckBESUxvN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAzKG6P M4jYcHNCVkeHUh?=
NBsusSR cell M3\WNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnLRTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOyCwTR?= NX21dGx5W0GQR1XS
ES7 cell MoLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX3kU2NjUW6qaXLpeIlwdiCxZjDoeY1idiCHU{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlU6KG6P NUDHNIFuW0GQR1XS
H-EMC-SS cell NUPwVIdGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?= M{jMRnNCVkeHUh?=
NCI-H1703 cell MmWwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfmTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N MWnTRW5ITVJ?
BHT-101 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlczKG6P MWrTRW5ITVJ?
SK-OV-3 cell M4e1dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnrzTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44PSCwTR?= NX3uWVNsW0GQR1XS
EW-24 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHjCcpNKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OyCwTR?= M4C5d3NCVkeHUh?=
PSN1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTWTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64OEBvVQ>? M1rWRXNCVkeHUh?=
OVCAR-8 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3ixc2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= MVzTRW5ITVJ?
NCI-H1563 cell NWf0clA1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\NOFZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU3OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMUOgcm0> Ml;tV2FPT0WU
SW756 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHRTY5pcWKrdHnvckBw\iCqdX3hckBUXzd3NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVMhdk1? NVzVXGt2W0GQR1XS
A375 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1LtZWlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVQhdk1? MkjPV2FPT0WU
Ca9-22 cell M1T1UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYX2SoJNUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJ3IH7N NVTJemdpW0GQR1XS
SW1990 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NITWdnRKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUm5NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOzJibl2= MVTTRW5ITVJ?
ES4 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfXb3dKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|khdk1? MYLTRW5ITVJ?
HCE-T cell NXTCcGFCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUTmTFRWUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDVibl2= M1\HUHNCVkeHUh?=
MOLT-16 cell NHHjXY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYnJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlU{KG6P NH\HUnVUSU6JRWK=
HSC-4 cell M4XlWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jV[mlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlghdk1? MUnTRW5ITVJ?
NCI-SNU-1 cell MkfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\VT3MyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lki2JI5O NGnTSJFUSU6JRWK=
EW-11 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn36TY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPUBvVQ>? MXzTRW5ITVJ?
HT-1080 cell NXvzU215T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rIfWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2= M{jobXNCVkeHUh?=
MES-SA/Dx5 cells NIf1bllEgXSxdH;4bYNqfHliYYPzZZk> M{XSTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GWy2VQT;EfFUh[2WubIOsJGlEPTB;NTDuUS=> NHHmOGUzOzl|N{m4NS=>
SW1710 cell M4n0NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXW0fI41UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF4IH7N MVvTRW5ITVJ?
EW-1 cell NG\GR|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PKW2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlQhdk1? NUjWSItuW0GQR1XS
BV-173 cell NX3K[|Z[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MljvTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P MXHTRW5ITVJ?
TE-8 cell NHPXclhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;3TWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFEhdk1? NWq2dGlmW0GQR1XS
G-401 cell NVPad21OT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60N{BvVQ>? M2DUXXNCVkeHUh?=
KOSC-2 cell NXLwcpVkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXLJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFUhdk1? MVLTRW5ITVJ?
HuCCT1 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mm\1TY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P NHXRR4ZUSU6JRWK=
FADU cell NGq1RplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDCTY5pcWKrdHnvckBw\iCqdX3hckBHSUSXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OkBvVQ>? NXjyR2VTW0GQR1XS
MHH-ES-1 cell MlvxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH\tSItKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54OTDuUS=> MXLTRW5ITVJ?
ES3 cell NIW3dVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHLzVFhKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|khdk1? M3njVHNCVkeHUh?=
OVCAR-4 cell M{jQSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{C0[mlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDdibl2= MnfWV2FPT0WU
HD-MY-Z cell NEPLbmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTER5I5UW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57MTDuUS=> M3n4XXNCVkeHUh?=
human JAR cell M1zsdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmH3TY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm3JI5O MkOxV2FPT0WU
A427 cell MnPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XtfGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNFchdk1? MXjTRW5ITVJ?
697 cell NHTkNopIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF;FNm9KdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVMhdk1? NY\lZXJxW0GQR1XS
OVCAR-3 cell MoH5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfJS5RKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJibl2= MXvTRW5ITVJ?
human NB14 cell NELBRnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTxU21KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P MkPTV2FPT0WU
GB-1 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWLZZ5c3UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?= NXTKc2tlW0GQR1XS
COR-L105 cell Mmi4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXpZ2ZNUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwN{[gcm0> NXfZU3hrW0GQR1XS
647-V cell MkXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3r6SmlvcGmkaYTpc44hd2ZiaIXtZY4hPjR5LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlkhdk1? Mnr1V2FPT0WU
human K5 cell Ml3QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVrsZo11UW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUegcm0> NWXCbVlUW0GQR1XS
DMS-273 cell NHrnWVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3LU[2lvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUK3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2= NGT0PHVUSU6JRWK=
UM-UC-3 cell MlHOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnS4TY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= NUX6S5FrW0GQR1XS
HEL cell M1O4Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4foZmlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz6wPEBvVQ>? NGXYVlFUSU6JRWK=
human KU-19-19 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4C3RWlvcGmkaYTpc44hd2ZiaIXtZY4hU1VvMUmtNVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB7IH7N NY\VVZgyW0GQR1XS
MC-IXC cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYK5PYN7UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjF5IH7N Mmn0V2FPT0WU
human H4 cell MnTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1zPOGlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkK1JI5O NH3JenZUSU6JRWK=
NUGC-3 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTYTY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P NX3NXWtbW0GQR1XS
CHP-212 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUm0V2pSUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|NDDuUS=> MYLTRW5ITVJ?
human SW982 cell NUn4W4JnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEDVO3ZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= MnKyV2FPT0WU
C-33-A cell Mm\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLYNGlKdmirYnn0bY9vKG:oIHj1cYFvKENvM{OtRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPThibl2= MU\TRW5ITVJ?
PC-3 cell NFTDTGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXXW[lQ2UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= NGOyTVhUSU6JRWK=
COLO-684 cell NIO4[HlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXviUJBrUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTlwMkGgcm0> MW\TRW5ITVJ?
SNU-387 cell M3u0OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\idpFKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N M4fTXHNCVkeHUh?=
U251 cell M3;5b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGHSWWJKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Mlg3KG6P NXjHV4NUW0GQR1XS
A673 cell NWXwSGloT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX;RPJc6UW6qaXLpeIlwdiCxZjDoeY1idiCDNkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPiCwTR?= MlPrV2FPT0WU
human T47D cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXsW4J7UW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2= MWLTRW5ITVJ?
A549 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O Mmf1V2FPT0WU
PC-14 cell M3jXU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnLTY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0Mlc{KG6P NFjkV|FUSU6JRWK=
A704 cell M4LWbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV7NN292UW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvPDVibl2= NI\nXoRUSU6JRWK=
MCF7 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEH6SmpKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= Ml3mV2FPT0WU
PC3 cells NYDadW9kTnWwY4Tpc44h[XO|YYm= Moq0TY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> NInPTGszOTN2MU[3OS=>
F-36P cells NITaeppRem:uaX\ldoF1cW:wIHHzd4F6 NX3lZYR1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?= MknQNlE{PDF4N{W=
OCI-AML2 cells M4jRXnBzd2yrZnXyZZRqd25iYYPzZZk> M3HDUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWFOVDJiY3XscJMtKEmFNUC9NE4{PSEQvF2= M4HE[VIyOzRzNke1
K562 cells NXfLbIxVWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHLINJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOsJGlEPTB;MUig{txO MoL3NlE{PDF4N{W=

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID